Syneron Medical Ltd announces that the ultrashort, 785-nm wavelength of its PicoWay picosecond laser has received approval from the US Food and Drug Administration (FDA).
This particular wavelength is designed to use a titanium sapphire laser to deliver ultra-short pulses of energy (ie, 300 picoseconds at 785 nm) to remove blue and green tattoo inks.
According to a media release from the Irvine, Calif-based company, the addition of PicoWay’s third wavelength completes the PicoWay laser platform, allowing for the comprehensive removal and treatment of all colors of tattoos and pigmented lesions. The PicoWay picosecond laser previously received FDA clearance for the removal of tattoos in November 2014 and the treatment of pigmented lesions in April 2015.
The FDA approval was supported by results from a study that included 15 patients and 22 tattoos, 18 of which contained blue and green inks. A blinded evaluation of tattoo clearance from independent board-certified physicians suggests that 83% of the treated blue/green tattoos had “good” to “complete” response after two treatments with the PicoWay 785-nm laser. These results were similar to findings from a blinded evaluation. Patients reported no complications, and no discomfort to mild discomfort for the majority of treatments, the release continues.
“With the addition of this third wavelength, PicoWay can now provide practices with the ability to provide comprehensive removal and treatment of all colors of tattoos and skin pigmentation. We look forward to making this feature available to new and existing PicoWay customers in the U.S. beginning in the fourth quarter,” states Amit Meridor, CEO of Syneron Medical, in the release.
For more information, visit Syneron Medical Ltd.
[Source(s): Syneron Medical Ltd, PR Newswire]